How well does Vafseo(Vadadustat) work?

This section summarizes the efficacy of VAFSEO from clinical trials.

Clinical Efficacy

The efficacy of VAFSEO was established in two global, active-controlled trials (INNO2VATE-1 and INNO2VATE-2) involving adults with dialysis-dependent CKD. VAFSEO was non-inferior to darbepoetin alfa in increasing and maintaining hemoglobin levels within the target range over the evaluation periods (Weeks 24-36 and 40-52). The therapy was also non-inferior to darbepoetin alfa regarding the risk of major adverse cardiovascular events (MACE), which includes all-cause mortality, non-fatal myocardial infarction, and non-fatal stroke.